Jason S. Lewis, PhD

Professor of Radiochemistry and Radiopharmacy in Radiology

Radiology

Memorial Sloan Kettering Cancer Center

Contact & profiles

Clinical profile ↗

Appointments

Professor of Radiochemistry and Radiopharmacy in RadiologyPrimary
Radiology · 2013–
Professor
Weill Cornell Graduate School — Pharmacology · 2015–
Professor of Radiochemistry and Radiopharmacy in Radiology
NewYork-Presbyterian Hospital

Past Appointments

Associate Professor of Radiochemistry and Radiopharmacy in Radiology
Radiology · 2009–2013
Assistant Professor of Radiochemistry and Radiopharmacy in Radiology
Radiology · 2008–2009

Centers

Clinical & Translational Science Center

Education

Ph.D.
University of Kent (United Kingdom), 1997
M.Sc.
University of Essex (United Kingdom), 1993
B.Sc.
University of Essex (United Kingdom), 1992

Highlights

1
Molecular imaging and biology · 2020
JSJason S. Lewis
PMID: 31001765PMCID: PMC6805144DOISenior author77 citations
2
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
SCSebastian Carrasco JSJason S. Lewis
PMID: 41537706PMCID: PMC12921459DOISenior author2 citations
3
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
SCSebastian Carrasco BZBrian Zeglis YJYelena Janjigian JSJason S. Lewis
PMID: 41748291PMCID: PMC13138102DOISenior author2 citations

Publications

380

Funding

Active

5 grants

MPI
Cancer Engineering Training Program
NCI · 2021–2031 · via NIH RePORTER
No publications yet
T32CA254875-06
MPI
Developmental Research Program
NCI · 2022–2027 · via NIH RePORTER
No publications yet
P50CA257881-05
PI
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin
NCI · 2020–2026 · via NIH RePORTER
No publications yet
R01CA244233-05
PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging
NCI · 2019–2026 · via NIH RePORTER
No publications yet
R35CA232130-07
MPI
Radiochemistry and Molecular Imaging Probes
NCI · 1997–2025 · via NIH RePORTER
No publications yet
P30CA008748-58

Completed grants (14)

MPI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer
NCI · 2018–2024 · via NIH RePORTER
No publications yet
U01CA221046-05
PI
Histopathologic validation of 89Zr-DFO-HuMab-5B1 PET/CT imaging in CA 19-9 positive pancreatic cancer
NCI · 2018–2024 · via NIH RePORTER
No publications yet
R01CA222049-02
MPI
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab
NCI · 2016–2023 · via NIH RePORTER
No publications yet
R01CA204167-05
PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zrrovalpituzumab, a DLL3-targeting monoclonal antibody
NCI · 2017–2021 · via NIH RePORTER
No publications yet
R01CA213448-04
MPI
Developmental Program
NCI · 2015–2021 · via NIH RePORTER
No publications yet
U54CA199081-05
PI
Bifunctional ligand development for targeted Positron Emission Tomography (PET) using Zirconium-89
NCI · 2016–2020 · via NIH RePORTER
No publications yet
R21CA201999-02
PI
Imaging VEGFR-1 in early metastatic lesions
NCI · 2017–2020 · via NIH RePORTER
No publications yet
R21CA216761-02
MPI
Biomarkers for predicting response to Hsp90 therapy
NCI · 2013–2019 · via NIH RePORTER
No publications yet
R01CA172546-05
PI
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET
NCI · 2013–2019 · via NIH RePORTER
No publications yet
R01CA176671-05S1
PI
World Molecular Imaging Congress 2015: Precision Medicine Visualized
NCI · 2015–2016 · via NIH RePORTER
No publications yet
R13CA200270-01
MPI
Cyclotron Radiochemistry and Chemistry
NCI · 2000–2016 · via NIH RePORTER
No publications yet
P50CA086438-14
PI
Novel Adjuvant Discovery in Vaccine Therapy
NIAID · 2010–2015 · via NIH RePORTER
No publications yet
R01AI085622-04
PI
PET Imaging of Cancer with pH (Low) Insertion Peptide (pHLIP)
NCI · 2010–2014 · via NIH RePORTER
No publications yet
R01CA138468-04
PI
Beta Imager 2000Z Digital Imaging System
NCRR · 2005–2005 · via NIH RePORTER
No publications yet
S10RR021007-01

Mentoring

12 All publications with mentees →

KT
Kathryn Tully
Pharmacology (PhD) · Class of 2021
- Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer.
  Nature communications · 2022
- Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity.
  Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
- Antibody-Based Molecular Imaging
  Molecular Imaging Principles and Practice · 2021
View all 8 →
VN
Veronica Nagle
Pharmacology (PhD) · Class of 2021
- Noninvasive Imaging of CD4+ T Cells in Humanized Mice.
  Molecular cancer therapeutics · 2022
- Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe.
  Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
- ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
  Molecular cancer therapeutics · 2021
View all 8 →
JK
Joshua Korsen
Pharmacology (PhD) · Class of 2022
- Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
  Proceedings of the National Academy of Sciences of the United States of America · 2022
- Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
- Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity.
  Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
View all 7 →
TH
Tran Hoang
Pharmacology (PhD) · Class of 2025
- Delta-like Ligand 3-Directed ²²⁵Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
- CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
- Click Chemistry and Radiochemistry: An Update.
  Bioconjugate chemistry · 2023
View all 4 →
KM
Kyeara Mack
Pharmacology (PhD) · Class of 2023
- Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
- ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
  Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
- ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
  Molecular cancer therapeutics · 2021
View all 4 →
JH
Justin Hachey
Pharmacology (PhD) · Class of 2025
- IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
View all 1 →
JW
Juliana Welk
Pharmacology (PhD)
- Delta-like Ligand 3-Directed ²²⁵Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
View all 1 →
OF
Olivia Friedl
Pharmacology (PhD)
- Trop-2.2-Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model.
  Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
View all 1 →
AW
Aidan Wirrick
Pharmacology (PhD)
CH
Christine Habjan
Pharmacology (PhD)
OM
Olufolake Majekodunmi
Pharmacology (PhD)
RP
Rachel Payne
Pharmacology (PhD)